Korean Journal of Radiology

  • 제25권9호
  • /
  • Pages.859-864
  • /
  • 2024
  • /
  • 1229-6929(pISSN)
  • /
  • 2005-8330(eISSN)
대한영상의학회 (The Korean Society of Radiology)
권호 표지
DOI QR코드

DOI QR Code

Determining Progressive Disease Using RANO 2.0-Further Clarifications and Explanations

  • Ji Eun Park (Department of Radiology and Research Institute of Radiology, University of Ulsan College of Medicine, Asan Medical Center) ;
  • Yae Won Park (Department of Radiology and Research Institute of Radiological Science and Center for Clinical Imaging Data Science, Yonsei University College of Medicine) ;
  • Young-Hoon Kim (Department of Neurosurgery, University of Ulsan College of Medicine, Asan Medical Center) ;
  • Sang Woo Song (Department of Neurosurgery, University of Ulsan College of Medicine, Asan Medical Center) ;
  • Chang-Ki Hong (Department of Neurosurgery, University of Ulsan College of Medicine, Asan Medical Center) ;
  • Jeong Hoon Kim (Department of Neurosurgery, University of Ulsan College of Medicine, Asan Medical Center) ;
  • Ho Sung Kim (Department of Radiology and Research Institute of Radiology, University of Ulsan College of Medicine, Asan Medical Center)
  • 투고 : 2024.05.21
  • 심사 : 2024.06.10
  • 발행 : 2024.09.01
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

키워드

과제정보

This research was supported by the National Research Foundation of Korea (NRF) grant funded by the Korean government (MSIP) (grant number: RS-2023-00208227 and RS-2023-00305153).

참고문헌

  1. Won SE, Suh CH, Kim S, Park HJ, Kim KW. Summary of key points of the response assessment in neuro-oncology (RANO) 2.0. Korean J Radiol 2024;25:407-411
  2. Wen PY, van den Bent M, Youssef G, Cloughesy TF, Ellingson BM, Weller M, et al. RANO 2.0: update to the response assessment in neuro-oncology criteria for high- and low-grade gliomas in adults. J Clin Oncol 2023;41:5187-5199
  3. Wen PY, Macdonald DR, Reardon DA, Cloughesy TF, Sorensen AG, Galanis E, et al. Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol 2010;28:1963-1972
  4. van den Bent MJ, Wefel JS, Schiff D, Taphoorn MJ, Jaeckle K, Junck L, et al. Response assessment in neuro-oncology (a report of the RANO group): assessment of outcome in trials of diffuse low-grade gliomas. Lancet Oncol 2011;12:583-593
  5. Ellingson BM, Wen PY, Cloughesy TF. Modified criteria for radiographic response assessment in glioblastoma clinical trials. Neurotherapeutics 2017;14:307-320
  6. Ellingson BM, Gerstner ER, Lassman AB, Chung C, Colman H, Cole PE, et al. Hypothetical generalized framework for a new imaging endpoint of therapeutic activity in early phase clinical trials in brain tumors. Neuro Oncol 2022;24:1219-1229
  7. Shidoh S, Savjani RR, Cho NS, Ullman HE, Hagiwara A, Raymond C, et al. Relapse patterns and radiation dose exposure in IDH wild-type glioblastoma at first radiographic recurrence following chemoradiation. J Neurooncol 2022;160:115-125
  8. Taal W, Brandsma D, de Bruin HG, Bromberg JE, Swaak-Kragten AT, Smitt PA, et al. Incidence of early pseudo-progression in a cohort of malignant glioma patients treated with chemoirradiation with temozolomide. Cancer 2008;113:405-410
  9. Louis DN, Perry A, Wesseling P, Brat DJ, Cree IA, Figarella-Branger D, et al. The 2021 WHO classification of tumors of the central nervous system: a summary. Neuro Oncol 2021;23:1231-1251
  10. Wen PY, van den Bent M, Vogelbaum MA, Chang SM. RANO 2.0: the revised response assessment in neuro-oncology (RANO) criteria for high- and low-grade glial tumors in adults designed for the future. Neuro Oncol 2024;26:2-4